These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31893354)

  • 1. Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study.
    Floridia M; Dalzero S; Giacomet V; Tamburrini E; Masuelli G; Savasi V; Spinillo A; Tassis B; Franceschetti L; Degli Antoni AM; Sansone M; Guaraldi G; Vimercati A; Meloni A; Ravizza M;
    Infection; 2020 Apr; 48(2):249-258. PubMed ID: 31893354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes.
    European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group
    AIDS; 2019 Feb; 33(2):295-304. PubMed ID: 30562172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
    Senise JF; Castelo A; Martínez M
    AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
    Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
    J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
    Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
    Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth.
    Szyld EG; Warley EM; Freimanis L; Gonin R; Cahn PE; Calvet GA; Duarte G; Melo VH; Read JS;
    AIDS; 2006 Nov; 20(18):2345-53. PubMed ID: 17117021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
    Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
    BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRTI)?
    Pozniak AL
    HIV Med; 2000; 1 Suppl 1():7-10. PubMed ID: 11737361
    [No Abstract]   [Full Text] [Related]  

  • 15. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new comprehensive HIV-1 genotypic drug resistance assay for all commercially available reverse transcriptase, protease and integrase inhibitors in patients infected with group M HIV-1 strains.
    Chrysostomou AC; Topcu C; Stylianou DC; Hezka J; Kostrikis LG
    Infect Genet Evol; 2020 Jul; 81():104243. PubMed ID: 32061896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database.
    Saint-Lary L; Diallo A; de Monteynard LA; Paul C; Marchand L; Tubiana R; Warszawski J; Mandelbrot L; Rekacewicz C; Petrov-Sanchez V; Faye A; Sibiude J; Dabis F; Sommet A; Leroy V
    Br J Clin Pharmacol; 2022 Mar; 88(3):942-964. PubMed ID: 34505718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
    Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
    Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis.
    Saint-Lary L; Benevent J; Damase-Michel C; Vayssière C; Leroy V; Sommet A
    BMC Pregnancy Childbirth; 2023 Jan; 23(1):80. PubMed ID: 36717801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.